Tyruko Європейський Союз - данська - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Lumigan Європейський Союз - данська - EMA (European Medicines Agency)

lumigan

abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - reduktion af forhøjet intraokulært tryk i kronisk åbenvinklet glaukom og okulær hypertension (som monoterapi eller som supplerende terapi til beta-blokkere).

Amiodarone "Orion" 50 mg/ml koncentrat til injektions-/infusionsvæske, opløsning Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

amiodarone "orion" 50 mg/ml koncentrat til injektions-/infusionsvæske, opløsning

orion corporation - amiodaronhydrochlorid - koncentrat til injektions-/infusionsvæske, opløsning - 50 mg/ml

Gemkabi 38 mg/ml koncentrat til infusionsvæske, opløsning Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

gemkabi 38 mg/ml koncentrat til infusionsvæske, opløsning

fresenius kabi ab - gemcitabinhydrochlorid - koncentrat til infusionsvæske, opløsning - 38 mg/ml